Royal Infirmary and University of Edinburgh, Edinburgh, Scotland.
Oregon Health & Science University, Portland, OR.
Chest. 2018 Apr;153(4):986-993. doi: 10.1016/j.chest.2018.01.014. Epub 2018 Jan 31.
In bronchiectasis due to cystic fibrosis (CF) and other causes, airway clearance is one of the mainstays of management. We conducted a systematic review on airway clearance by using non-pharmacological methods as recommended by international guidelines to develop recommendations or suggestions to update the 2006 CHEST guideline on cough.
The systematic search for evidence examined the question, "Is there evidence of clinically important treatment effects for non-pharmacological therapies in cough treatment for patients with bronchiectasis?" Populations selected were all patients with bronchiectasis due to CF or non-CF bronchiectasis. The interventions explored were the non-pharmacological airway clearance therapies. The comparison populations included those receiving standard therapy and/or placebo. Clinically important outcomes that were explored were exacerbation rates, quality of life, hospitalizations, and mortality.
In both CF and non-CF bronchiectasis, there were systematic reviews and overviews of systematic reviews identified. Despite these findings, there were no large randomized controlled trials that explored the impact of airway clearance on exacerbation rates, quality of life, hospitalizations, or mortality.
Although the cough panel was not able to make recommendations, they have made consensus-based suggestions and provided direction for future studies to fill the gaps in knowledge.
在囊性纤维化(CF)和其他原因引起的支气管扩张症中,气道清除是管理的主要方法之一。我们按照国际指南的建议,对非药物方法的气道清除进行了系统评价,以制定建议或意见来更新 2006 年 CHEST 指南中关于咳嗽的内容。
系统搜索证据的问题是:“对于囊性纤维化或非囊性纤维化支气管扩张症患者的咳嗽治疗,非药物治疗在咳嗽治疗方面是否有临床重要的治疗效果证据?” 选择的人群是所有因 CF 或非 CF 引起的支气管扩张症患者。探索的干预措施是非药物气道清除疗法。比较人群包括接受标准治疗和/或安慰剂的人群。所探讨的临床重要结果是加重率、生活质量、住院率和死亡率。
在 CF 和非 CF 支气管扩张症中,都确定了系统评价和系统评价综述。尽管有这些发现,但没有大型随机对照试验探讨气道清除对加重率、生活质量、住院率或死亡率的影响。
尽管咳嗽小组未能提出建议,但他们提出了基于共识的建议,并为未来的研究提供了方向,以填补知识空白。